Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study

Massin, Pascale; Bandello, Francesco; Garweg, Justus G; Hansen, Lutz L; Harding, Simon P; Larsen, Michael; Mitchell, Paul; Sharp, Dianne; Wolf-Schnurrbusch, U E K; Gekkieva, Margarita; Weichselberger, Andreas; Wolf, Sebastian (2010). Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes care, 33(11), pp. 2399-405. Alexandria, Va.: American Diabetes Association 10.2337/dc10-0493

Full text not available from this repository. (Request a copy)

The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Wolf-Schnurrbusch, Ute and Wolf, Sebastian

ISSN:

0149-5992

Publisher:

American Diabetes Association

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:08

Last Modified:

06 Dec 2013 13:19

Publisher DOI:

10.2337/dc10-0493

PubMed ID:

20980427

Web of Science ID:

000284516400020

URI:

https://boris.unibe.ch/id/eprint/429 (FactScience: 198899)

Actions (login required)

Edit item Edit item
Provide Feedback